leadf
logo-loader
viewSynairgen PLC

Synairgen says inhaled drug included in a major US government-sponsored coronavirus trial

The drug discovery and development specialist said researchers will assess SNG001’s potential to help patients not yet requiring hospitalisation

Synairgen PLC -

Synairgen PLC (LON:SNG) has said its inhaled interferon beta-1a respiratory treatment has been included in a US government-sponsored coronavirus (COVID-19) clinical trial.

The drug discovery and development specialist said researchers will assess SNG001’s potential to help COVID-19 patients not yet requiring hospitalisation.

The ACTIV-2 study, sponsored by America’s National Institute of Allergy and Infectious Diseases, is part of the US National Institutes of Health and is being used to accelerate the development of the most promising treatment candidates.

The adaptive, randomised, blinded, placebo-controlled trial will recruit 220 people for phase II analysis. Positive results from the earlier clinical stage will see SNG001's progression to phase III.

In a statement, Synairgen chief executive Richard Marsden said: “The inclusion of our inhaled interferon beta-1a treatment in the US Government-funded ACTIV-2 trial reflects the strong interest that our phase II data has generated and the company’s strong belief that this drug could play a vital role in the treatment of COVID-19.

“As an inhaled treatment, SNG001 offers ease of use that makes it possible for patients to administer it conveniently at home, reducing the risk of virus transmission during hospital visits and relieving the major logistical strain on healthcare systems.”

Synairgen said earlier this month that it had begun dosing in a 610-patient, international phase III trial. This will assess the efficacy of the inhaled interferon beta drug in hospitalised patients with COVID-19.

Quick facts: Synairgen PLC

Price: 165 GBX

AIM:SNG
Market: AIM
Market Cap: £329.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read